Los Angeles Capital Management
ITOS

Los Angeles Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Los Angeles Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,398
Closed -$377K – 1230
2024
Q2 		$377K Sell
25,398
-4,000
-14% -$57.3K ﹤0.01% 939
2024
Q1 		$401K Buy
+29,398
New +$320K ﹤0.01% 932
2023
Q4 		– Sell
-105,554
Closed -$1.16M – 1183
2023
Q3 		$1.16M Sell
105,554
-4,468
-4% -$57.1K ﹤0.01% 593
2023
Q2 		$1.46M Buy
110,022
+2,800
+3% +$39.9K 0.01% 560
2023
Q1 		$1.46M Buy
107,222
+19,024
+22% +$341K 0.01% 564
2022
Q4 		$1.72M Buy
88,198
+372
+0.4% +$7.27K 0.01% 554
2022
Q3 		$1.67M Sell
87,826
-36,971
-30% -$852K 0.01% 547
2022
Q2 		$2.57M Buy
124,797
+92,192
+283% +$2.19M 0.01% 473
2022
Q1 		$1.05M Buy
+32,605
New +$1.18M ﹤0.01% 735

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Los Angeles Capital Management's ITOS Position: Q3 2024 in Review

Los Angeles Capital Management sold out of iTeos Therapeutics (ITOS) in Q3 2024, closing a stake of 25,398 shares — an estimated $377K sold.

Los Angeles Capital Management first reported a position in ITOS in Q1 2022 and held it in 9 quarters. The position peaked at $2.57M in Q2 2022. 150 funds tracked by Wall St. Rank hold ITOS as of Q3 2024.

  • Los Angeles Capital Management reported no remaining iTeos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Los Angeles Capital Management sold 25,398 iTeos Therapeutics shares in Q3 2024, an estimated $377K.
  • Los Angeles Capital Management first reported a position in iTeos Therapeutics in Q1 2022 and held it in 9 quarters.
  • Los Angeles Capital Management's iTeos Therapeutics position peaked at $2.57M in Q2 2022.
  • 150 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2024.

Based on Los Angeles Capital Management's 13F filing for Q3 2024, filed 4 Nov 2024.